Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Independent UK
The Independent UK
Health
Rebecca Thomas and Ella Pickover

New Alzheimer’s drug rejected for NHS use – because it’s not worth the money

Donanemab, also known as Kisunla, slows decline in memory of Alzheimer’s patients - (PA)

A new Alzheimer’s drug has been rejected for widespread use in the NHS in England after the health spending watchdog ruled it “does not currently demonstrate value for the NHS”.

The new drug, called donanemab, has been rejected for use in England’s health services by the National Institute for Health and Care Excellence (NICE).

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.